Corton Capital Inc. Makes New Investment in Sarepta Therapeutics, Inc. $SRPT

Corton Capital Inc. bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the second quarter, Holdings Channel.com reports. The firm bought 10,188 shares of the biotechnology company’s stock, valued at approximately $174,000.

Several other institutional investors also recently modified their holdings of SRPT. State of Michigan Retirement System lifted its holdings in Sarepta Therapeutics by 1.3% during the first quarter. State of Michigan Retirement System now owns 22,900 shares of the biotechnology company’s stock worth $1,461,000 after acquiring an additional 300 shares during the period. Louisiana State Employees Retirement System increased its position in shares of Sarepta Therapeutics by 1.1% during the 1st quarter. Louisiana State Employees Retirement System now owns 26,800 shares of the biotechnology company’s stock valued at $1,710,000 after purchasing an additional 300 shares during the last quarter. Ancora Advisors LLC raised its stake in shares of Sarepta Therapeutics by 150.0% during the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 300 shares during the period. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Sarepta Therapeutics by 5.9% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 6,387 shares of the biotechnology company’s stock worth $408,000 after buying an additional 358 shares during the last quarter. Finally, Brooklyn Investment Group grew its position in Sarepta Therapeutics by 450.4% during the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 590 shares during the period. 86.68% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on SRPT. JPMorgan Chase & Co. raised shares of Sarepta Therapeutics from an “underweight” rating to a “neutral” rating and set a $24.00 price objective on the stock in a research report on Tuesday, July 29th. Leerink Partners lifted their price target on shares of Sarepta Therapeutics from $12.00 to $15.00 and gave the stock a “market perform” rating in a report on Tuesday, September 9th. Piper Sandler upped their price objective on Sarepta Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, October 30th. Citigroup began coverage on Sarepta Therapeutics in a research report on Tuesday, July 22nd. They issued a “sell” rating for the company. Finally, Royal Bank Of Canada boosted their target price on Sarepta Therapeutics from $14.00 to $16.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and seven have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $33.67.

Sarepta Therapeutics Trading Down 33.7%

Shares of SRPT stock opened at $16.20 on Wednesday. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of -18.62 and a beta of 0.51. The company’s fifty day simple moving average is $20.32 and its two-hundred day simple moving average is $26.28. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $138.81. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). The company had revenue of $399.36 million during the quarter, compared to the consensus estimate of $331.51 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.Sarepta Therapeutics’s revenue was down 14.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.62 earnings per share. As a group, analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.